UPDATE: Noble Capital Starts Cocrystal Pharma, Inc.. (COCP) at Outperform, Earlier Today

(Updated - June 16, 2020 10:24 AM EDT)

(Updated to correct company name, was reported COOP earlier)

Noble Capital analyst Ahu Demir initiates coverage on Cocrystal Pharma, Inc.. (NASDAQ: COCP) with a Outperform rating and a price target of $5.00.

Analyst comments: "Cocrystal remains under the Street's radar with its pipeline. Its versatile technology platform enables growth in new directions. As we look forward, we believe that three ongoing preclinical programs (influenza, coronavirus, and norovirus) may provide dynamic catalysts for the near/medium term. In addition, one IND filing (influenza program), expected in Q4 2020, provides fundamental depth to future value."

For an analyst ratings summary and ratings history on Mr. Cooper Group Inc. click here. For more ratings news on Mr. Cooper Group Inc. click here.

Shares of Mr. Cooper Group Inc. closed at $13.11 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ladenburg Thalmann Starts Spire (SR) at Neutral
• JPMorgan Downgrades Boyd Gaming (BYD) to Neutral
• H.C. Wainwright Downgrades Argo Blockchain ADR (ARBK) to Neutral